Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy
Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.
Further Information: PDF
Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639
Contact
Dr. Rolf Hecker
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Trotting robots reveal emergence of animal gait transitions
A four-legged robot trained with machine learning by EPFL researchers has learned to avoid falls by spontaneously switching between walking, trotting, and pronking – a milestone for roboticists as well…
Innovation promises to prevent power pole-top fires
Engineers in Australia have found a new way to make power-pole insulators resistant to fire and electrical sparking, promising to prevent dangerous pole-top fires and reduce blackouts. Pole-top fires pose…
Possible alternative to antibiotics produced by bacteria
Antibacterial substance from staphylococci discovered with new mechanism of action against natural competitors. Many bacteria produce substances to gain an advantage over competitors in their highly competitive natural environment. Researchers…
